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Chemical Purification of 
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Four terbium radioisotopes (149, 152, 155, 161Tb) constitute a potential theranostic quartet for cancer 
treatment but require any derived radiopharmaceutical to be essentially free of impurities. Terbium-155 
prepared by proton irradiation and on-line mass separation at the CERN-ISOLDE and CERN-MEDICIS 
facilities contains radioactive 139Ce16O and also zinc or gold, depending on the catcher foil used. A 
method using ion-exchange and extraction chromatography resins in two column separation steps 
has been developed to isolate 155Tb with a chemical yield of ≥95% and radionuclidic purity ≥99.9%. 
Conversion of terbium into a form suitable for chelation to targeting molecules in diagnostic nuclear 
medicine is presented. The resulting 155Tb preparations are suitable for the determination of absolute 
activity, SPECT phantom imaging studies and pre-clinical trials.
Four terbium isotopes (149,152,155,161Tb) have been identified as having suitable physical properties (i.e. half-life 
(T1/2); emission type and quantity of emitted radiation) for use in cancer treatment and diagnosis. (Table 1)1–3. 
Initial pre-clinical trials1 have highlighted all four isotopes as being theranostic candidates using a folate-receptor 
derivative, cm09. Terbium isotopes form stable complexes with DOTA-containing targeting agents which show 
favourable in-vivo stability, emphasising their suitability for clinical use1,4,5. Terbium-155 (T1/2 = 5.32 d3) offers 
promise as an imaging tracer in single photon emission computed tomography (SPECT), with initial pre-clinical 
studies indicating excellent image quality even at low doses4. The administration of 155Tb alongside a therapeutic 
terbium isotope would give a theranostic pair with identical chemical properties; this is particularly advantageous 
as it facilitates the application of personalised medicine.
Terbium-161 can be generated via neutron activation of a 160Gd target and subsequent decay of the 161Gd 
product to give the desired 161Tb (160Gd(n,γ)161Gd (β−) 161Tb)5. The other isotopes (149,152,155Tb) have been 
produced mainly via a proton-induced spallation reaction on a tantalum target combined with on-line mass 
separation at the CERN-ISOLDE facility6–8. A high percentage of the 1.4 GeV protons delivered by the proton 
synchrotron booster do not interact with the ISOLDE targets and therefore, the CERN-MEDICIS facility was 
established to produce isotopes for medical applications by inducing spallation reactions in a secondary target. 
At CERN-MEDICIS, off-line mass separation is applied to isolate isotopes of the same A/q value6,7. Terbium-155 
sources used in this study were collected after mass-separation by implantation of the ion beam (155 A/q) into 
zinc-coated gold foils. Further chemical separation is still required as mass separation is unable to differentiate 
between isobaric and pseudo-isobaric species. Removal of the foil matrix is also required.
Alternative methods of producing these isotopes have been investigated (Table 2)8–15. However, full-scale pro-
duction at a radionuclide purity sufficient for clinical studies has not yet been demonstrated.
All lanthanides, especially neighbouring elements, have similar chemical properties due to small differences 
in their ionic size/charge ratio, making the isolation of high purity individual lanthanide solutions challenging16. 
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They exist predominately in the III+ oxidation state under aqueous conditions. The exceptions are europium, 
which can be selectively reduced to Eu(II) under strongly reducing conditions, and cerium, which can be easily 
oxidised to Ce(IV). Changes in oxidation state markedly influence chromatographic behaviour and this can be 
exploited when developing separation methods.
A well-known method of separating lanthanide elements utilises cation-exchange chromatography with 
α-hydroxyisobutyric acid (α-HIBA) eluent and provides good separation even from neighbouring elements1,5,8. 
However, the process is slow and requires precise control of chemical conditions (pH and α-HIBA concentration) 
to give optimal yield and purity. Attempts to accelerate separation tend to compromise terbium recovery.
A significant 139Ce (T1/2 = 137.6 d17) impurity exists in 155Tb sources from CERN-ISOLDE and 
CERN-MEDICIS owing to formation of the pseudo-isobaric species, 139Ce16O, which cannot be removed by mass 
separation. Given its half-life, it constitutes an increasing proportion of overall source activity during transport 
and storage. In this study, we present a simple method for producing radiologically pure terbium preparations 
in a chemical form suitable for chelation to targeting molecules as well as for absolute activity measurements 
and phantom imaging studies. Our aim was to develop a robust, efficient and rapid method capable of isolating 
terbium from the foil matrix as well as from 139Ce by selective oxidation. Therefore, ion-exchange and extraction 
chromatography resins were chosen based on their selectivity for tetravalent over trivalent species.
Results
Chemical separation. Batch separation. In the presence of an oxidant (sodium bromate, NaBrO3) and in 
HNO3 solutions commercial UTEVA, TEVA and TK100 extraction resins (Triskem International) and AG1 anion 
exchange resin (BioRad) all showed pronounced cerium adsorption selectivity over terbium (Fig. 1). The results 
imply oxidation of cerium to Ce(IV) was achieved, with terbium remaining in the trivalent state (Tb(III)).
High Ce adsorption (Kd = 100–1,000) was observed at high HNO3 concentrations (8–10 M) on all four resins, 
whilst terbium adsorption remained minimal (Kd = 0.1–10) across the concentration range (Fig. 2). The best 
separation resolutions (Equation (2), SR > 100) were obtained using TEVA and UTEVA resins at high HNO3 
concentrations; further studies were conducted on these resins using pre-packed cartridges.
Kinetic studies. UTEVA extraction chromatography resin was chosen to demonstrate kinetic behaviour with the 
rate of cerium adsorption studied in 10 M HNO3/0.1 M NaBrO3 solutions; rapid adsorption (<60 s) was observed 
(Fig. 3a). The rate of cerium oxidation was also studied in 10 M HNO3/0.1 M NaBrO3 solutions. Solutions were 
filtered under vacuum after a minimum of 60 s in contact with the resin. Rapid oxidation (<90 s) of cerium was 
observed (Fig. 3b).
Neither the rate of adsorption nor the rate of oxidation were limiting factors in the separation, suggesting that 
rapid column separation is achievable under these conditions.
Isotope T1/2
Decay mode 
(branching 
ratio) Energy of particle radiation
Energy of main 
γ and X-ray 
emissions (keV)
Application
α therapy PET SPECT
β/auger 
therapy
149Tb 4.12 h α (16.7%) β
+ 
(7.1%)
Eα = 3.967 MeV
Eβ+mean = 730 keV
352 (29%)
165 (26%) x x
152Tb 17.5 h β+ (17%) Eβ+mean = 1.080 MeV 344 (64%) x
155Tb 5.32 d EC (100%) —
43 (86%)
49 (20%)
87 (32%)
105 (25%)
x
161Tb 6.89 d β− (100%) Eβ-mean = 154 keV
26 (23%)
45–46 (18%)
49 (17%)
75 (10%)
x x
Table 1. Physical properties of four terbium isotopes and their applications in nuclear medicine1,2. EC 
– electron capture; PET – positron emission tomography; SPECT – single photon emission computed 
tomography.
Isotope Nuclear reactions Production facility Incident particle energy References
149Tb
Ta(p,sp)149Tb Synchrotron 1.4 GeV (CERN) Allen et al.8
151Eu(3He, 5n)149Tb Cyclotron 40–70 MeV Zagryadskii et al.14
152Tb
Ta(p,sp)152Tb Synchrotron 1.4 GeV (CERN) Allen et al.8
155Gd(p,4n)152Tb Cyclotron 39 MeV Steyn et al.9
155Tb
Ta(p,sp)155Tb Synchrotron 1.4 GeV (CERN) Allen et al.8
155Gd(p,n)155Tb Cyclotron 11 MeV Vermeulen et al.13
153Eu(ɑ,n)155Tb Cyclotron 28 MeV Kazakov et al.12
161Tb 160Gd(n,γ)161Gd - > 161Tb Nuclear reactor (flux = 8 × 1014 neutrons cm−2 s−1) Lehenberger et al.5
Table 2. Established and alternative production methods for the four terbium isotopes.
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Column studies. Column-based separation using a commercially available pre-packed UTEVA cartridge (2 mL) 
provided effective isolation of terbium from cerium impurities. The elution profile (Fig. 4) shows that terbium 
(>99%) was removed in the load solution (10 mL, 8 M HNO3) and the subsequent wash solution (10 mL, 8 M 
HNO3) with minimal cerium impurities remaining (<0.002%). Cerium was successfully recovered by elution 
from the cartridge in hydrochloric solution (<10 mL, 0.1 M). The column-based separation was repeated using 
a pre-packed TEVA cartridge (2 mL); however, the separation achieved was less successful as ~0.1% Ce was 
detected in the Tb fraction under similar conditions (Fig. 4).
These column studies allowed the development of a separation scheme for the removal of 155Tb from both 
139Ce isotopic impurities and the zinc-plated gold catcher foil matrix (Fig. 5).
Figure 1. Distribution coefficients (Kd) for Ce(IV), Ce(III) and Tb(III) in HNO3 solutions on UTEVA 
extraction chromatography resin. (N = 3).
Figure 2. Distribution coefficients (Kd) of Ce(IV) and Tb(III) in HNO3 solutions on (a) AG1 ion exchange 
resin, (b) TEVA resin, (c) TK100 resin, (d) UTEVA resin. (N = 3).
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Validation with active 155Tb. The method has been validated on three sources (nominal 155Tb activity Bq – 
MBq) over a two year period. A mass separated source received from CERN-ISOLDE in 2017 (EOB - 07/09/2017 
18:42:00) contained a significant 139Ce impurity (A0(139Ce)/A0(155Tb) = 0.30 ± 0.02), Table 3). The scheme detailed 
in Fig. 5 removed 139Ce to the level of the Compton continuum background (DL,0(139Ce)/A0(155Tb) = 0.00021). 
Total terbium fraction recovery, R0,1(155Tb)/R0,2(155Tb), was 0.973+/− 0.038 with a radiochemical purity of 
99.98% (Table 3). This was consistent for all validation experiments.
Discussion
In many cases, it is essential that suitable radiochemical methods are available to provide radionuclides in suf-
ficient quantities with relatively high specific activity, radionuclidic and chemical purity to facilitate accurate 
pre-clinical and clinical study. The method described is able to produce high radiological purity 155Tb sources, 
suitable for absolute activity, nuclear data and ionisation chamber measurements. The sources are also suitable 
for bioconjugation, molecular chelation and SPECT imaging studies. Although the 139Ce impurity discussed here 
does not possess significant biological toxicity18, it is radioactive and, if not removed, would result in an unneces-
sary additional dose to the patient.
Currently, proton-induced spallation is the main route for producing 155Tb at CERN for (pre)-clinical studies. 
The chemical purification method proposed here (Fig. 5) allows the quantitative separation of 155Tb from a zinc 
and/or gold matrix and from 139Ce impurities produced by spallation at the CERN-ISOLDE and CERN-MEDICIS 
facilities. The method is rapid, simple and can also be used to recover a high purity 139Ce source; a useful standard 
in gamma spectrometry (Eγ = 165.86 keV, 79.90%)17.
The method has not yet been validated for the removal of other stable (e.g. 139La16O+, 155Gd+) or longer-lived, 
radioactive (e.g. 155Eu+) isobaric impurities; as with 139Ce16O, they would not be removed by mass separation. 
Such impurities might not pose a significant toxicological risk if they were to enter the body19,20 but nevertheless, 
would form stable complexes with DOTA (logK > 22)21 and DOTA-containing targeting molecules4 and could 
compete with the target terbium isotope(s), reducing their efficacy.
Figure 3. Kinetics of (a) the adsorption of Ce(IV) and Tb(III) onto UTEVA resin, and (b) the oxidation of 
cerium using sodium bromate. Measured as the distribution coefficient (Kd) as a function of time.
Figure 4. Elution profiles (N = 3) for Tb and Ce from a pre-conditioned 2 mL UTEVA cartridge (left) and a 
pre-conditioned 2 mL TEVA cartridge (right). Approximate flow rate = 0.3 mL/min.
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Materials and Methods
Chemicals. Standard element solutions at starting concentrations of 1000 ppm were purchased from Johnson 
Matthey and Fluka Analytical (Tb and Ce, respectively). Mixed standard solutions were prepared in HNO3 
(Trace Analysis Grade, Fisher Scientific) and diluted to the required concentration with ultrapure water (ELGA 
PURELAB Flex, Veolia Water, Marlow, UK, 18 MΩ cm, <5 ppb Total Organic Carbon). Anion exchange resin 
(Bio Rad AG1-X8, 100–200 mesh) and extraction chromatography resins (TEVA, TK100 and UTEVA, Triskem 
International 100–150 μm) were used throughout.
The 155Tb source was provided by CERN-ISOLDE and CERN-MEDICIS in the form of a zinc-coated gold foil. 
HCl (Trace Analysis Grade, Fisher Scientific) and HNO3 were used for foil dissolution and NaBrO3 (Alfa Aesar) 
for cerium oxidation.
Inductively coupled plasma mass spectrometry (ICP-MS). Measurement of stable 140Ce and 159Tb 
was carried out using a tandem ICP-MS/MS (Agilent 8800) equipped with a collision-reaction cell positioned 
between two quadrupole mass filters. The instument was run in Single Quad mode, with only the second mass fil-
ter operating. The instrument is fitted with a quartz double-pass spray chamber and a MicroMist nebuliser (Glass 
Expansion, Melbourne, Australia) and nickel sample and skimmer cones (Crawford Scientific, South Lanarkshire, 
UK). It was tuned daily using a mixed 1 ppb standard solution (Ce, Co, Li, Mg, Tl and Y in 2% v/v HNO3). No 
Figure 5. Final 155Tb separation scheme for CERN-ISOLDE and CERN-MEDICIS sources with an additional 
139Ce recovery step.
Isotope T1/2
Activity of material 
supplied (MBq)
Activity following 
separation
139Ce 136.7 d 2.79 ± 0.068 ≤1.90 kBq
155Tb 5.32 d 9.28 ± 0.63 9.03 ± 0.049 MBq
Table 3. Radioisotopic composition of a 155Tb source received from CERN-ISOLDE before and after chemical 
separation (reference time 2017-09-29 12:00 UTC).
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additional terbium-specific tuning was carried out. A 209Bi (10 ppb solution in 2% v/v HNO3) internal standard 
was used to monitor and correct for instrumental drift during longer runs. Blank HNO3 (2% v/v) solutions were 
monitored regularly to ensure no Ce or Tb cross-contamination during a run.
Gamma-ray spectrometry. An n-type HPGe γ-ray spectrometer with a resolution (FWHM) of 1.79 keV 
at 1.33 MeV and relative efficiency 28% was used to determine the 139Ce/155Tb activity ratio. The detection system 
set-up and full-energy peak efficiency calibration is described in detail by Collins et al.22.
The nuclear data (half-lives and γ-ray emission intensities) used to determine the activities of 155Tb and 139Ce 
were taken from the evaluated database of ENSDF and the DDEP, respectively3,17. As 139Ce could not be observed 
after the chemical separation, the activity ratio of the 139Ce/155Tb in the chemically separated solution was esti-
mated from the detection limit of the detector for 139Ce23.
Irradiation conditions and mass separation. Terbium-155 sources used in this study were produced 
at the CERN-ISOLDE and CERN-MEDICIS facilities. Three 155Tb sources were produced and provided to NPL 
for chemical separation between 2017 and 2018. The irradiation conducted at CERN-MEDICIS was as follows:
A high purity Ta metal target (Ta647M) made of 12 rolls of Ta foil (99.95% purity, 12 μm thick, 15 mm wide, 
2 cm diameter) with a total mass of 357 g was arranged in a 20 cm long Ta tube coupled to a rhenium surface 
ion source. The target was irradiated with 1.4 GeV protons delivered by the Proton Synchrotron Booster accel-
erator (CERN, Geneva). The CERN-MEDICIS irradiation target is located in the High Resolution Separator 
(HRS) beam dump position at ISOLDE (Fig. 6), and receives a fraction of the scattered 1.8 × 1018 protons down-
stream from a primary HRS target (623SiC, ISOLDE physics program). The irradiation was scheduled within the 
MED004 approved experiment and took place from 27th September to 1st October 2018. The irradiated target was 
then moved to the CERN-MEDICIS isotope mass separator in order to release and extract ion species selected 
at mass-to-charge ratio of 1556. The separated ions were collected on a zinc-plated gold foil and removed on 
3rd October. The following isotopes were implanted upon sample retrieval: 139Ce (implanted as 139Ce16O+): 6.9 
MBq; 155Dy: 3.6 MBq; 155Tb: 20 MBq. Upon reception at NPL, 155Dy had decayed below the detection limit (DL,0 
(155Dy) = 1.75 kBq).
Chemical separation. Batch separation studies. The adsorption of Tb and Ce onto ion exchange (AG1, 
BioRad) and extraction chromatography resins (TEVA, UTEVA and TK100, Triskem International) was studied 
over a range of HNO3 solution concentrations (2–10 M). Nitric acid solutions (2 mL) containing a mixture of 100 
ppb stable Ce and Tb were prepared. An aliquot was taken from each solution for ICP-MS measurement. The 
Figure 6. Top: Fluka simulation25,26 showing the incoming proton beam on an ISOLDE target (3.5 g/cm2 UCx 
for the purpose of the simulation) and intercepting the MEDICIS target downstream. Middle: Screenshot taken 
with the beam scanner, located before the implantation chamber. Beams at A/q = 154,155,156 are seen (153, 157 
partly visible). The collected beam is centred on A/q = 155, while isotopes present at other masses are physically 
removed from the implantation using mechanical slits located ahead of the foil. The horizontal scale is in mm. 
Bottom: Two zinc-coated gold foils in the collection chamber seen from the rear. The collection takes place on 
the foil located on the left.
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remaining solution was added to 0.1 g of resin (UTEVA, TEVA, TK100 or AG1). Sodium bromate (0.1 M, 0.03 g) 
was added to identical samples to assess changes in adsorption to the resin as a result of selective oxidation of Ce. 
In all cases, the samples were shaken and left to equilibrate for 24 h. After equilibration, the solutions were filtered 
to isolate the aqueous phase (Whatman 41 ashless filter paper, 20–25 μm pore size). An aliquot was taken from 
each sample, diluted with 2% HNO3 (2% v/v) and analysed by ICP-MS.
The adsorption of Tb and Ce onto each resin was quantified by calculating the distribution coefficient (Kd) 
using Eq. (1)24.
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Where (CPS)0 and (CPS)t are the concentrations of analyte in the aqueous phase before and after equilibration, 
respectively, V is the volume of solution (mL) and m is the mass of resin used (g).
The separation achievable in the different HNO3 solutions was quantified by calculating the separation factor 
using Eq. (2).
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Kinetic studies. In order to determine the rate at which Ce(IV) and Tb(III) are adsorbed onto UTEVA, a HNO3 
(10 M) solution containing 100 ppb Ce, 100 ppb Tb and sodium bromate (0.1 M) was left for 24 h to allow for the 
oxidation of Ce(III) to Ce(IV). Aliquots (2 mL) were added to vials containing UTEVA resin (0.1 g) and were 
left in static conditions before being filtered to isolate the aqueous phase at regular time intervals under vacuum 
(60 seconds–180 minutes).
Likewise, to determine the rate at which Ce is oxidised, an excess of sodium bromate (0.1 M, 0.03 g) was added 
to a HNO3 solution (2 mL, 10 M) containing 100 ppb Ce, 100 ppb Tb and 0.1 g of UTEVA resin. Repeat samples 
were left in static conditions before being filtered to isolate the aqueous phase at regular time intervals under 
vacuum (90 seconds - 180 minutes).
An aliquot of each filtrate was diluted with HNO3 (2% v/v) before analysis by ICP-MS. Distribution coeffi-
cients were calculated using Eq. (1).
Column studies. Column-based separation was studied using a pre-packed 2 mL UTEVA cartridge (50–100 µm, 
Triskem International). The resin was pre-conditioned with 8 M HNO3 (20 mL). A HNO3 solution (10 mL, 8 M) 
containing 0.1 M NaBrO3, 100 ppb Tb and 100 ppb Ce was loaded onto the resin. A wash solution of 10 mL 
8 M HNO3 was added to ensure removal of all Tb from the cartridge. Subsequent elution of Ce was achieved 
using 20 mL 0.1 M HCl. This separation method was also repeated using a pre-packed 2 mL TEVA cartridge 
(50–100 µm, Triskem International).
Throughout the separations, 1 mL fractions were collected, diluted with HNO3 (2% v/v) and analysed by 
ICP-MS in order to compile an elution profile. Column separations were carried out under gravity (approximate 
flow rate = 0.3 mL/min).
Method validation with active sample. Three zinc-coated gold foils containing 155Tb and 139Ce were 
received at NPL from CERN-ISOLDE and CERN-MEDICIS. The radionuclides were leached by dissolving the 
zinc layer in 20 mL 6 M HCl and the gold foil in 20 mL aqua regia. Both layers were dissolved in order to maxim-
ise the yield of terbium from the sources received. The combined solution was evaporated gently on a hot plate 
(~150 °C) to incipient dryness and re-dissolved in a 10 mL 8 M HNO3/0.1 M NaBrO3 solution. An ampoule was 
prepared for HPGe gamma spectrometry in order to quantify the activity of 155Tb and 139Ce present. After analy-
sis, the portion was recombined with the bulk solution.
A pre-packed 2 mL UTEVA cartridge (Triskem International, 50–100 µm) was conditioned with 20 mL 8 M 
HNO3. The 10 mL sample was then loaded onto the column and the fraction collected under gravity. The col-
umn was washed with 10 mL 8 M HNO3. This fraction was collected, under gravity, and combined with the 
load fraction. The combined fractions were evaporated gently on a hot plate (~150 °C) to incipient dryness and 
re-dissolved in 20 mL 0.1 M HCl.
An ampoule of the combined terbium fractions was prepared and analysed by HPGe gamma spectrometry 
in order to assess the resultant purity of the 155Tb source after separation. The terbium recovery was calculated 
as follows:
=
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where R0,1 and R0,2 are the count rates of the 105 keV gamma-ray emission before and after separation of the 
139Ce, respectively at the reference time 2017-09-29 12:00 UTC. N1 and N2 are the net peak areas of the 105 keV 
full-energy peak measured before and after separation, ΔtL,1 and ΔtL,1 are the measurement live times, m1 and m2 
are the measured active masses of solution, mD and mE are the total mass of solution used to dissolve the Zn layer 
of the target and eluent used in the chemical separation, respectively, λ is the decay constant of 155Tb, t1 and t2 are 
the time elapsed since the reference time and Δt1 and Δt2 are the measurement real times.
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Conclusion
A novel method has been developed for the isolation of 155Tb from sources produced at CERN-ISOLDE and 
CERN-MEDICIS, currently the main producers of the isotope. A high purity 155Tb preparation was successfully 
recovered from a zinc-coated gold matrix and from 139Ce impurities using a chromatography-based system. The 
method was shown to be capable of separating 100 ppb Tb and Ce in a 10 mL solution, equivalent to ~6 GBq 
155Tb and ~0.25 GBq 139Ce. The radiologically pure 155Tb preparation was subsequently used for absolute activity 
measurements and ion chamber measurements. The preparations are also suitable for phantom imaging and 
pre-clinical studies.
Data Availability
The data generated and analysed during this study are available, upon reasonable request, from the corresponding 
author.
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